D-1095-2017 Class II Terminated
FDA drug recall D-1095-2017 was initiated by Hetero USA Inc on Jul 20, 2017 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specification: single unknown impurity OOS 0.33% (Limit:NMT 0.20%W/W) at the three month stability point. The recall status is terminated (terminated Feb 27, 2019). Affected quantity: 5664 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 23, 2017
- Initiation Date
- Jul 20, 2017
- Termination Date
- Feb 27, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5664 bottles
Product description
Entecavir Tablets 0.5 mg, 30 tablets per container, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854. By: Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar - 509 301, India. NDC 31722-833-30
Reason for recall
Failed Impurities/Degradation Specification: single unknown impurity OOS 0.33% (Limit:NMT 0.20%W/W) at the three month stability point.
Distribution pattern
NJ
Code information
Lot # ENT17008, Exp 01/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1095-2017
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026